Eurosurveillance banner


Eurosurveillance invites authors to submit papers for a special issue on HIV/AIDS and other sexually transmitted infections (STI) in men who have sex with men (MSM). The topic is in line with the main theme of World AIDS Day 2009 events organised by the European Centre for Disease Prevention and Control and aims at drawing attention to the epidemiological importance of MSM in HIV and other STI and directing the ECDC activities to focus on main risk groups.

Eurosurveillance is planning to publish a special issue on Socio-economic determinants and infections diseases in Europe in spring 2010. For this reason Eurosurveillance invites interested scientists who have research findings in the area to submit papers for review and possible publication. The submission deadline now is 15 November.

The data from 27 European Union countries plus Iceland, Liechtenstein and Norway show that considerable progress has been made in preventing and controlling the disease. The number of newly diagnosed cases and the overall notification rate declined continuously in the past decade, and the notification rate in 2007 was 12% lower than in 2003. In spite of this decline, a total of 84,917 new cases of TB were registered in 2007 and a number of challenges hamper the progress towards the elimination of TB in the EU.

A number of bacterial and viral infections in pregnant women can have serious effects on the unborn child leading to impaired mental and physical health later in life. This week’s issue of Eurosurveillance is dedicated to infectious diseases in pregnancy.

The emergence and spread of antimicrobial resistance (AMR) is a growing problem in many European countries. To mark the very first European Antibiotic Awareness Day, on 18 November, the scientific journal Eurosurveillance runs a series of articles to highlight main aspects of the AMR problem in Europe. They will be published in two issues on 13 and 20 November 2008.

In preparation for the coming influenza season 2008-9, Eurosurveillance publishes a special issue on prevention of influenza by vaccination. Seasonal influenza poses a serious public health threat because of associated serious morbidity and mortality. In Europe, estimates suggest that influenza is responsible for around 40,000 to 220,000 excess deaths, depending on the severity of the epidemic.

Today Eurosurveillance is publishing a special issue dedicated to the widespread advances made in Europe in estimating the real number of newly acquired HIV infections based on an innovative approach called STARHS

To tie in with World Hepatitis Day on 19 May, the scientific journal Eurosurveillance is today publishing a special issue on viral hepatitis, highlighting issues and challenges related to hepatitis B and C.

On 17 April 2008, Eurosurveillance is publishing a special issue with articles on the measles situation in Europe. The publication is linked to European Immunisation Week which runs from 21-27 April.

World Tuberculosis Day on 24 March commemorates the date in 1882 when Robert Koch presented his findings of the causing agent of tuberculosis (TB) – Mycobacterium tuberculosis. In the run up of this day Eurosurveillance publishes a special issue on the situation of TB in Europe.

Today (6 March, 2008), Eurosurveillance, the European peer-reviewed journal of infectious diseases, publishes a special issue on meningococcal disease. It includes two in-depth articles and an editorial by the European Centre for Disease Prevention and Control (ECDC).


In this issue


Home Eurosurveillance Edition  2009: Volume 14/ Issue 29 Article 3 Printer friendly version
Back to Table of Contents
Previous Download (pdf) Next

Eurosurveillance, Volume 14, Issue 29, 23 July 2009
Rapid communications
Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009
  1. Field Epidemiology Training program, National Institute of Infectious Diseases (NIID), Tokyo, Japan
  2. Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan

Citation style for this article: Komiya N, Gu Y, Kamiya H, Yahata Y, Matsui T, Yasui Y, Okabe N. Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. Euro Surveill. 2009;14(29):pii=19272. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19272
Date of submission: 16 July 2009

This report describes the clinical characteristics of influenza A(H1N1)v virus infection in Osaka. By the end of May, 171 cases had been reported in Osaka. Most patients were from one school. No patient had a serious underlying medical condition.Clinical symptoms were mild and resembled those of seasonal influenza. The sensitivity of the rapid antigen test was 77%. Antivirals were given to the majority of the cases. Early antiviral treatment may have shortened the duration of fever.


Background

In Japan, the first case of influenza A (H1N1)v was found at Narita International Airport quarantine station on 9 May. The patient was a high school student who had traveled to Canada [1]. The first non-travel case was detected on 16 May in Kobe. On the same day, subsequent cases were found in Osaka prefecture, about 30 km from Kobe [2]. In the beginning, the authorities decided to hospitalise all patients for the purpose of isolation, based on the infection control law [3,4]; consequently 18 patients were hospitalised in Osaka. On 18 May, Osaka prefecture revised its hospitalisation policy based on clinical severity because of the rapid increase of the number of cases. Patients with mild symptoms were treated as outpatients and placed under medical observation at home. By 20 July, 847 cases had been reported in Osaka. Among them, 171 cases had been reported by the end of May. Most patients were adolescents. Of the 171 cases (including 13 who resided in other prefectures) 105 were from one school. This paper summarises the clinical characteristics of influenza A(H1N1)v cases reported in Osaka by the end of May.

Investigation in Osaka

The National Institute of Infectious Diseases (NIID) in Japan started an investigation on 17 May. By then, two clusters had been found in Osaka. One was the previously mentioned school and the other was a nearby elementary school. Although the numbers of cases were increasing day by day, most cases were linked to these two clusters. We focused the NIID investigation on these clusters; the remaining cases were investigated by the local health center.

Case definition
A case of influenza A (H1N1)v is defined as a person with influenza A(H1N1)v virus infection confirmed by real-time RT-PCR.

Cluster 1
・Secondary school: 1,934 students and 143 employees.
・Study population: 105 cases (103 students, 2 teachers), male: 83, female: 22
・Median age: 16 years (range: 13 to 53 years)
・One patient had mild asthma. No patient had a serious underlying medical condition.

Data collection
Direct face-to-face interviews were carried out by the NIID with 17 hospitalised patients, and telephone interviews were performed with 88 home-quarantined patients by school teachers with our technical assistance.

Cluster 2
・Elementary school: 624 pupils (no information on employees).
・Study population: 7 cases (pupils only), male: 2 , female: 5
・Median age: 11 years. (range: 9 to 12 years)
・One patient had asthma. No patient had a serious underlying medical condition.

Data collection
Direct face-to-face interviews with the patients and their parents were conducted by the NIID or the local health center.

Other cases
・Study population: 59 cases (31 secondary school students, 7 elementary school pupils, 21 other), male: 33, female: 33
・Median age: 15 years (range: 6 to 48 years)
・No patient had a serious underlying medical condition.

Data collection
Direct face-to-face interviews with the patients (or their parents) were conducted by the NIID or the local health center.

Clinical findings

Symptoms and laboratory data
Fever, cough and sore throat were most frequently observed (Table 1, 2). Most of the cases had clinical features similar to seasonal influenza [5]. 19.8% of cluster 1 and 14% of cluster 2 cases had diarrhoea, while usually fewer (approximately 10%) patients have diarrhoea with seasonal influenza in Japan [6]. Standard blood test results of 12 hospitalised patients showed no results specific to this virus. Cluster 2 included the first cases of the outbreak of influenza A (H1N1)v in children in Japan. No significant differences were found between age groups in symptoms or severity of illness.

Table 1. Clinical symptoms of cases of influenza A(H1N1)v in cluster 1 (secondary school n=105), Osaka, Japan, May 2009



Table 2. Clinical symptoms of cases of influenza A(H1N1)v in cluster 2 (elementary school, all ≤12 years old, n=7), Osaka, Japan, May 2009



Rapid antigen test
Rapid antigen tests were conducted in the majority of cases. However, information on when this was performed was available for 35 cases only. The sensitivity of the rapid antigen test depended on when the kit was used; it was highest on day 1 (82.4%) and was relatively low on days 0 (75%) and 2 (60%) (Table 3). It is difficult to determine the accuracy of the rapid antigen test kit from the data presented here because of insufficient information (e.g. type of kit used). However, we conclude that the rapid antigen test cannot be used to rule out the possibility of influenza A(H1N1)v virus infections.

Table 3. Rapid kit test results of cases of influenza A(H1N1)v in Osaka, Japan, May 2009 (n=35)



Treatment
Among 171 cases in Osaka, antivirals were given to 165 (96%); oseltamivir to 95 (56%) and zanamivir to 68 (40%) of the cases. Further two cases took zanamivir at first, and then switched to oseltamivir. Information on the duration of symptoms under treatment was available for 90 cases. Of these 90 cases, 44 received oseltamivir, 45 zanamivir and one switched from zanamivir to oseltamivir in the middle of clinical course. There was no significant difference in the duration of fever between two medications (oseltamivir 2.32 days, zanamivir 2.36 days, P=0.88, t test). Nevertheless, the results indicated that earlier administration of antivirals contributed to a reduction in the duration of fever (Table 4). However, this result is not enough to completely evaluate the effectiveness of antivirals, because we could not compare these groups to a group without prescriptions. Also, we could not assess whether antivirals reduced severity of illness, since the symptoms of all cases were mild.

Table 4. Prescription day and duration of fever in cases of influenza A(H1N1)v in Osaka, Japan, May 2009 (n=90)



Outcome
A few patients had underlying medical conditions, such as asthma. All these cases had a relatively quick and uneventful recovery. Because of the infection control law, 18 patients were hospitalised but all had mild symptoms and had no clinical indication for admission.

Conclusions

In Osaka, the majority of influenza A (H1N1)v cases occurred among healthy children and adolescents. The proportion of patients who had diarrhoea was slightly higher compared to that observed in seasonal influenza patients, but other clinical symptoms resembled those of seasonal influenza. No severe cases occurred. The results of the rapid antigen test were not sufficient to diagnose influenza A (H1N1)v virus infections. Antivirals were given to the majority of the cases. The analysis showed that early antiviral treatment shortened the duration of fever. One limitation of our study was that the methods of collection of clinical information were not standardised. Further studies are necessary to determine the accuracy of rapid antigen tests and the effectiveness of antivirals.

Acknowledgements
We express deep appreciation for the cooperation and support of the members and staffs of Osaka City General Hospital, Toyonaka Municipal Hospital, Sakai Municipal Hospital, Osaka Prefecture, Osaka Prefecture Public Health Centre, Osaka City Public Health Centre, Sakai City Public Health Centre, and Takatsuki City Public Health Centre.


References

  1. Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan. Epidemiological investigation of a novel influenza A (H1N1) outbreak detected by entry screening, Narita, Japan, 2009 -- Preliminary report. Available from: http://idsc.nih.go.jp/disease/swine_influenza_e/idsc_e2009/epi_narita.html
  2. Shimada T, Gu Y, Kamiya H, Komiya N, Odaira F, Sunagawa T, et al. Epidemiology of influenza A(H1N1)v virus infection in Japan, May - June 2009. Euro Surveill. 2009;14(24):pii=19244. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19244
  3. Ministry of Health, Labour, and Welfare (MHLW) of Japan. Official notification about   amendment of the Quarantine Law [in Japanese]. 12 May 2008. Available from:  http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/pdf/16-04.pdf
  4. Ministry of Health, Labour, and Welfare (MHLW) of Japan. Pandemic Influenza Preparedness Action Plan of the Japanese Government. October 2007. Available from:  http://www.mhlw.go.jp/english/topics/influenza/dl/pandemic02.pdf
  5. Call SA, Vollenweider MA, Hornung CA, Simel DL, Mckinney WP. Does this patient have influenza? JAMA. 2005;293(8):987-97.
  6. Kawai N, Iwaki N, Kawashima T, Satoh I, Sigematsu T, Kondoh K, et al. Clinical symptoms of influenza infection in the 2002-2003 season [in Japanese]. Kansenshogaku Zasshi. 2004;78(8):681-9.


Back to Table of Contents
Previous Download (pdf) Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the Editorial team or the institutions with which the authors are affiliated. Neither the ECDC nor any person acting on behalf of the ECDC is responsible for the use which might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our Website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2008 All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.